×
About 1,010 results

ALLMedicine™ Acute Graft Versus Host Disease Center

Research & Reviews  262 results

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
https://clinicaltrials.gov/ct2/show/NCT04144036

Aug 3rd, 2022 - Eligible patients will receive Neihulizumab weekly, for up to four doses. Responding patients, and patients with stable disease should receive all four weekly doses. Patients with skin only disease that clinically progresses by one stage (e.g, fro...

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT03057054

Jul 21st, 2022 - PRIMARY OBJECTIVE: I. To determine efficacy of orally-administered Lactobacillus plantarum (LBP) in preventing the development of gastrointestinal (GI) acute graft versus host disease (aGvHD) in children and adolescents undergoing alternative dono...

Outcomes of haploidentical peripheral stem cell transplantation with combination of pos...
https://doi.org/10.1016/j.leukres.2022.106918
Leukemia Research; Barkhordar M, Kasaeian A et. al.

Jul 18th, 2022 - In the evolution of haploidentical hematopoietic stem cell transplantation (haplo-HSCT), In vivo T-cell modulation with concomitant use of anti-thymocyte globulin (ATG) and high-dose post-transplant cyclophosphamide (PTCy) provides a novel promisi...

Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Mye...
https://clinicaltrials.gov/ct2/show/NCT05457556

Jul 14th, 2022 - PRIMARY OBJECTIVES: I. To compare the 1-year cumulative incidence of severe GVHD (from day of HCT) defined as Grade III-IV acute GVHD (aGVHD) and/or chronic GVHD (cGVHD) that requires systemic immunosuppression and to compare the disease free surv...

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT04006652

Jul 13th, 2022 - Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member represents a significant breakthrough in the field. Haploide...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  133 results

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
https://clinicaltrials.gov/ct2/show/NCT04144036

Aug 3rd, 2022 - Eligible patients will receive Neihulizumab weekly, for up to four doses. Responding patients, and patients with stable disease should receive all four weekly doses. Patients with skin only disease that clinically progresses by one stage (e.g, fro...

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT03057054

Jul 21st, 2022 - PRIMARY OBJECTIVE: I. To determine efficacy of orally-administered Lactobacillus plantarum (LBP) in preventing the development of gastrointestinal (GI) acute graft versus host disease (aGvHD) in children and adolescents undergoing alternative dono...

Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Mye...
https://clinicaltrials.gov/ct2/show/NCT05457556

Jul 14th, 2022 - PRIMARY OBJECTIVES: I. To compare the 1-year cumulative incidence of severe GVHD (from day of HCT) defined as Grade III-IV acute GVHD (aGVHD) and/or chronic GVHD (cGVHD) that requires systemic immunosuppression and to compare the disease free surv...

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT04006652

Jul 13th, 2022 - Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member represents a significant breakthrough in the field. Haploide...

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
https://clinicaltrials.gov/ct2/show/NCT04744116

Jul 12th, 2022 - PRIMARY OBJECTIVE: I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities. OUTLINE: Patients are randomized to 1 of 3 arms. ARM 1: Patients receive ruxolitinib o...

see more →

News  8 results

Itolizumab Under Further Investigation in EQUATOR Trial as Frontline aGVHD Treatment
https://www.onclive.com/view/itolizumab-under-further-investigation-in-equator-trial-as-frontline-agvhd-treatment

Apr 1st, 2022 - The addition of itolizumab to standard-of-care (SOC) corticosteroids vs placebo will be evaluated in patients with acute graft-versus-host disease (aGVHD), as part of the phase 3 EQUATOR trial (NCT05263999), according to John Koreth, MBBS, DPhil, ...

AML: Similar posttransplant short-term outcomes after azacitidine-venetoclax vs. intensive chemotherapy
https://www.mdedge.com/hematology-oncology/article/249256/aml/aml-similar-posttransplant-short-term-outcomes-after

Dec 1st, 2021 - Key clinical point: In patients with acute myeloid leukemia (AML), short-term posttransplant outcomes seemed similar in those who achieved first complete remission (CR1) with either first-line therapy with 5-azacitidine combined with venetoclax (a.

Prophylactic Strategies in Graft vs Host Disease Management
https://www.onclive.com/view/prophylactic-strategies-in-graft-vs-host-disease-management

Nov 15th, 2021 - Transcript: Corey Cutler, MD, MPH, FRCPC: GVHD [graft versus host disease] prophylaxis is universal. The only time that we don’t do prophylaxis is when you have a transplant from identical twins, or when you are using the patient as their own don...

T-Cell Depleted Allografts Lessen GVHD in MDS
https://www.onclive.com/view/t-cell-depleted-allografts-lessen-gvhd-in-mds

Dec 20th, 2020 - Roni Tamari, MD Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced ...

Genomic Era Reaches Pediatric Oncology
https://www.onclive.com/view/genomic-era-reaches-pediatric-oncology

Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...

see more →